Prostate-Specific Antigen — Prostate health biomarker

Prostate-specific antigen is a serine protease whose biological function is to liquefy semen in the male reproductive tract. While small quantities naturally enter the circulatory system, disruptions to normal prostatic architecture—such as inflammation, benign enlargement, or the presence of invasive cancer cells—allow larger amounts to leak into the bloodstream.

In oncological practice, serum PSA levels are quantified in nanograms per millilitre (ng/mL). Elevated levels suggest prostatic tissue disruption but do not exclusively confirm the presence of cancer, requiring clinicians to interpret results in context with digital rectal examination findings, prostate volume, age, and historical trend lines.

PSA testing provides crucial objective information across the entire cancer care trajectory. For screening, it identifies potential tumours early, often before physical symptoms manifest. For individuals undergoing treatment for confirmed prostate cancer, falling PSA levels generally signify that therapies are succeeding, whereas a persistent rise after surgery or radiotherapy can signal recurrence long before tumours become visible on standard radiological imaging.

PSA is measured via routine venepuncture in clinical laboratories. Complementary analyses include free-versus-total PSA ratio, PSA velocity, and PSA density. When PSA is elevated, modern clinical pathways incorporate multiparametric magnetic resonance imaging and subsequent targeted transrectal or transperineal core needle prostate biopsies for definitive histological evaluation.

PSA is specifically linked to prostate adenocarcinoma, the predominant form of prostate cancer. It is not generally utilised for evaluating other cancer types, although extremely rare cases of neuroendocrine tumours of non-prostatic origin may occasionally interact with diagnostic markers. Its primary oncological utility remains firmly rooted in managing prostate diseases.

PSA dynamics directly shape prostate cancer treatment strategies. Low-risk tumours identified primarily through modest PSA elevations may qualify for active surveillance instead of immediate intervention. In active disease, rising PSA levels prompt initiation or escalation of radical prostatectomy, radiotherapy, androgen deprivation therapy, or novel androgen receptor pathway inhibitors.